Hepatitis B virus envelope protein-derived peptide–HLA-A*02:01 complex (HBV Env–HLA-A*02:01)

The "Hepatitis B virus envelope protein–HLA-A*02:01 complex" refers to a structure in which a peptide fragment from the HBV envelope protein is bound and presented by the HLA-A*02:01 molecule on the surface of infected cells. This complex is recognized by cytotoxic CD8+ T cells, triggering immune-mediated destruction of the infected cells. Such HBV-derived peptide–HLA complexes are central targets for immune recognition, immunotherapy, and vaccine design. The specific peptide sequence can vary, encompassing various immunodominant epitopes within the HBV envelope protein that are compatible with HLA-A*02:01 binding motifs[1][4][7][8].

Other names

HBV Env peptide–HLA-A*02:01Hepatitis B virus envelope epitope–HLA-A*02:01HBV S antigen–HLA-A*02:01 peptide complex

Recognition by cytotoxic T cells: CD8+ T lymphocytes recognize the viral peptide on infected cells and initiate cell killing. Induction of antiviral immune response: The complex can be used in vaccine design or TCR-based therapies to trigger immune responses against HBV-infected cells.